SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc. (Amendment)

2/14/23 12:38:10 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RARE alert in real time by email

SC 13G/A 1 rare13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6) ULTRAGENYX PHARMACEUTICAL INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 90400D108 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 766,521 6. Shared Voting Power* 0 7. Sole Dispositive Power* 4,096,388 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 4,096,388 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 5.8% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: ULTRAGENYX PHARMACEUTICAL INC Item 1(b) Address of Issuer's Principal Executive Offices: 60 LEVERONI COURT, NOVATO, CALIFORNIA 94949 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates) Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 90400D108 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 14, 2023 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2022

Get the next $RARE alert in real time by email

Recent Analyst Ratings for

$RARE

Date	Price Target	Rating	Analyst
6/6/2024	$56.00 → $67.00	Neutral → Buy	Goldman
4/22/2024	$77.00	Outperform	RBC Capital Mkts
12/8/2023	$72.00	Overweight	Wells Fargo
6/14/2023	$96.00	Outperform	Credit Suisse
6/6/2023	$60.00 → $80.00	In-line → Outperform	Evercore ISI
4/26/2023	$114.00	Overweight	Cantor Fitzgerald
1/18/2023	$90.00	Buy	Canaccord Genuity
12/30/2022	$82.00	Buy	H.C. Wainwright

More analyst ratings

SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for
$RARE

$RARE
Financials

Live finance-specific insights

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

$RARE
Leadership Updates

Live Leadership Updates

Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy

Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President

Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors

$RARE
Press Releases

Fastest customizable press release news feed in the world

Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

$RARE
SEC Filings

Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEFA14A filed by Ultragenyx Pharmaceutical Inc.

SEC Form DEF 14A filed by Ultragenyx Pharmaceutical Inc.

$RARE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP and Chief Medical Officer Crombez Eric sold $28,901 worth of shares (762 units at $37.93), decreasing direct ownership by 0.55% to 71,530 units (SEC Form 4)

Chief Financial Officer Horn Howard sold $72,114 worth of shares (1,785 units at $40.40), decreasing direct ownership by 2% to 106,169 units (SEC Form 4)

CBO & EVP Kassberg Thomas Richard was granted 18,443 shares, sold $253,779 worth of shares (6,028 units at $42.10) and covered exercise/tax liability with 508 shares, increasing direct ownership by 5% to 264,730 units (SEC Form 4)

$RARE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Ultragenyx Pharma upgraded by Goldman with a new price target

RBC Capital Mkts initiated coverage on Ultragenyx Pharma with a new price target

Wells Fargo initiated coverage on Ultragenyx Pharma with a new price target

$RARE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc.